Stockscreener 앱 받기
27.80
0.00%
0.00
시간 외 거래:
27.90
0.10
+0.36%
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares - MarketBeat
Roivant (NASDAQ: ROIV) president exercises 200K options and sells 200K shares - Stock Titan
Roivant Sciences Insider Sold Shares Worth $1,200,573, According to a Recent SEC Filing - marketscreener.com
Insider Sell Alert: Melissa Epperly Sells 41,861 Shares of Roiva - GuruFocus
Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 41,861 Shares - MarketBeat
Roivant Sciences (ROIV) director sells 41,861 common shares - Stock Titan
Roivant secures FDA priority review for dermatomyositis treatment - MSN
Aug Catalysts: Can Roivant Sciences Ltd outperform under higher oil prices2026 PreEarnings & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rockefeller Financial files to sell 200,000 Roivant shares | ROIV SEC FilingForm 144 - Stock Titan
Aug Reactions: Is Roivant Sciences Ltd stock undervalued right nowWeekly Stock Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Bamco Inc. NY Acquires 105,000 Shares in Roivant Sciences Ltd. - National Today
105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY - MarketBeat
Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? - MSN
Roivant Sciences Ltd. $ROIV Shares Purchased by HighVista Strategies LLC - MarketBeat
Roivant Sciences Ltd. $ROIV is Foursixthree Capital LP's 7th Largest Position - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Sold by Prosight Management LP - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Bought by Integral Health Asset Management LLC - MarketBeat
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent LitigationSlideshow (NASDAQ:ROIV) 2026-03-13 - Seeking Alpha
Roivant Sciences stock hits all-time high at 30.31 USD - Investing.com Nigeria
Roivant Sciences Hits New 52-Week High at $30.30, Up 180.72% - Markets Mojo
Roivant Sciences stock hits all-time high at 30.31 USD By Investing.com - Investing.com Canada
Leerink Partners maintains Roivant Sciences (ROIV) outperform recommendation - MSN
Roivant at Leerink Conference: Strategic Transformation Insights - Investing.com Australia
Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week HighHere's Why - MarketBeat
(ROIV) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Roivant Sciences stock hits all-time high at 29.23 USD - Investing.com Nigeria
WINTON GROUP Ltd Purchases 335,269 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright - The Globe and Mail
Aug Rallies: Can Roivant Sciences Ltd. sustain earnings growthQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Roivant Sciences Hits New 52-Week High at $29.20, Up 170.89% - Markets Mojo
Dow Update: Can Roivant Sciences Ltd outperform under higher oil pricesJuly 2025 Intraday Action & Weekly High Return Forecasts - baoquankhu1.vn
Neo Ivy Capital Management Has $3.59 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Blue Owl Capital Holdings LP Acquires New Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) reports Q3 loss, misses revenue estimates - MSN
Sentiment Review: Is Roivant Sciences Ltd stock undervalued right nowGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
HC Wainwright Expects Stronger Earnings for Roivant Sciences - MarketBeat
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Roivant Sciences Hits New 52-Week High at $29.82, Up 179% - Markets Mojo
Roivant Sciences Hits Day High with Strong 6% Intraday Surge - Markets Mojo
Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026 - Meyka
Roivant Sciences stock hits all-time high at 29.23 USD By Investing.com - Investing.com Canada
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds By Investing.com - Investing.com South Africa
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength - Yahoo Finance
Key facts: Roivant Sciences secures $2.25B settlement; boosts buyback to $1B; price target raised to $34 - TradingView
Moderna to pay up to $2.25B to settle COVID-19 patents case - BioWorld MedTech
Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - TradingView
TD Cowen reiterates Roivant Sciences stock rating on drug launch timing - Investing.com Australia
TD Cowen reiterates Roivant Sciences stock rating on drug launch timing By Investing.com - Investing.com South Africa
Moderna gains as Arbutus/ Genevant settlement removes major financial risk - Seeking Alpha
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $34.00 at HC Wainwright - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Purchased by TD Asset Management Inc - MarketBeat
A Glimpse Into The Expert Outlook On Roivant Sciences Through 7 Analysts - Benzinga
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds - Investing.com Australia
What Roivant Sciences (ROIV)'s Priority FDA Review for Brepocitinib in Dermatomyositis Means For Shareholders - Yahoo Finance
ROIV Analyst Rating Update: HC Wainwright & Co. Raises Price Tar - GuruFocus
The Bull Case For Roivant Sciences (ROIV) Could Change Following Brepocitinib’s Priority Review In Dermatomyositis - simplywall.st
Jefferies Maintains Buy on Roivant Sciences Ltd. (ROIV) March 2026 - Meyka
Wolfe Research reiterates Roivant Sciences stock rating at Outperform - Investing.com Australia
Wolfe Research reiterates Roivant Sciences stock rating at Outperform By Investing.com - Investing.com India
1.20%
0.06%
자본화:
|
볼륨(24시간):